Developing Effective Hit- Finding Strategies eBook
"Discovering and developing a new drug is a complex and time-consuming endeavour. Pharmaceutical and biotechnology companies are under tremendous pressure to be first to market. Yet, many of the best-validated targets are in challenging protein classes with little precedence for small molecule ligand binding. This creates a significant hurdle for hit finding. A carefully devised strategy is, therefore, essential when looking for validated hit series with a good chance of being developed into drug-like compounds."
Sygnature Discovery, Developing Effective Hit-Finding Strategies eBook.
Fill in the form below to receive your eBook download link via email.
Read the eBook to discover
- Practical knowledge of effective hit-finding strategies, including high-throughput screening and structure-based drug design, to optimize your drug discovery efforts.
- Cutting-edge advancements in drug discovery, including techniques such as targeted protein degradation and phenotypic cell assays which enable you to adjust your approach and discover new targets and mechanisms.
- Expert guidance and practical recommendations from an industry professional to navigate the complex drug discovery process more effectively and enhance your hit-finding endeavours.
Hit-Finding Services from Sygnature Discovery
Unlocking the path to identifying robust hit series with exceptional longevity, Sygnature Discovery employs a repertoire of proven hit-finding approaches meticulously customised to your specific target. These versatile methodologies can be seamlessly implemented in combination or independently and strategically aligned with the unique requirements of your project.
By working with us you will have access to:
Design-Make-Test-Evaluate
Our high-efficiency Design–Make–Test-Evaluate cycle, as a result of team integration and co-localization, rapidly generates high-quality data for expert evaluation.
Scale-Up Capability
Our scale-up capability allows rapid delivery of non-GLP safety assessment batch and transfer of a robust route to a Contract Manufacturing Organization for GMP synthesis.
Track Record
A strong track record - we have delivered 40 high-quality clinical candidates for clients, a large proportion of which have already progressed to human dosing.
The Team
Our experienced teams avoid common pitfalls and interrogate the available data, providing innovative solutions to the challenges encountered.
Delivering for our customers - a proven track record
-1.png?width=862&height=596&name=Performance%20graph%20only%20(with%20atom%20filigrane)-1.png)
